US FDA advisers back the same Covid-19 vaccine for initial shots, boosters
Sign up now: Get ST's newsletters delivered to your inbox
The agency is trying to simplify its Covid-19 vaccine policy and considers recommending Americans get an annual booster shot.
PHOTO: REUTERS
WASHINGTON – Advisers to the US Food and Drug Administration (FDA) on Thursday unanimously voted in favour of targeting the same coronavirus strain for initial Covid-19 vaccine doses and boosters going forward, but some expressed scepticism about whether all Americans need to receive the shots annually.
The agency is trying to simplify its Covid-19 vaccine policy as it considers whether to recommend Americans get an annual booster shot for the virus.
But several members of the expert advisory group asked for more robust data on benefits of annual shots for younger, healthier people.
“We’re in a very different place. We have a lot of population immunity,” said Dr Hayley Gans, professor of paediatrics at Stanford University Medical Centre. “Now that people are immune, how long does that last?”
Vaccine makers Pfizer – with partner BioNTech – and Moderna introduced updated versions of their Covid-19 vaccines in late 2022, tailored to target Omicron variants as well as the original coronavirus.
In the United States, those were used only as booster shots.
The FDA advisory group unanimously backed using those shots for the primary series for those who have yet to be vaccinated against Covid-19 as well.
The FDA said it envisioned holding a meeting later in 2023 to determine the composition of shots for autumn, although some vaccine makers might be able to produce updated shots more quickly.
Pfizer-BioNTech and Moderna were able to produce the currently available messenger RNA boosters in about three months in 2022, but Novavax said on Thursday it would require six months to make a new version of its protein-based Covid-19 vaccine designed to match circulating coronavirus variants.
Dr Peter Marks, director of the FDA’s Centre for Biologics Evaluation and Research, said the agency would consider an earlier timeline for vaccines like Novavax’s following the company’s manufacturing assessment.
Health officials in the Biden administration have suggested that annual, updated Covid-19 booster shots could provide a high level of protection against severe disease.
REUTERS
